All Stories

  1. Fair Allocation of Scarce Attention-Deficit/Hyperactivity Disorder Stimulants
  2. Bedless Adolescent Psychiatry: The Ethical Challenge to End Psychiatric Boarding
  3. Investigators' Experiences with IRB Oversight of Psychedelic Research
  4. Indigenous Wisdom and Underground Knowledge Are Exceptional
  5. Ethics in Psychedelic Science
  6. Challenges in Assessing Affect and Values in Decision-Making Capacity
  7. The safety of supported psilocybin use in Oregon
  8. Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias
  9. A Call for Greater Regulation of Digital Mental Health Technologies
  10. Online Peer Support for Mental Health in the Early Months of the COVID-19 Pandemic: A Retrospective Analysis (Preprint)
  11. When patients refuse COVID-19 testing, quarantine, and social distancing in inpatient psychiatry: clinical and ethical challenges
  12. Ethical Advocacy Across the Autism Spectrum: Beyond Partial Representation
  13. Prescribing medical cannabis: ethical considerations for primary care providers
  14. Decision-Making Capacity Will Have a Limited Effect on Civil Commitment Practices
  15. Authors' reply
  16. Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker
  17. Mass Shootings and Psychiatric Deinstitutionalization, Here and Abroad
  18. A pragmatist's guide to the assessment of decision-making capacity
  19. Challenges in Research on Suicide Prevention—Reply
  20. Ethical considerations on the complicity of psychologists and scientists in torture
  21. Medicaid’s Institutions for Mental Diseases (IMD) Exclusion Rule: A Policy Debate—Argument to Repeal the IMD Rule
  22. Are Clinicians Obliged to Disclose Their Immigration Status to Patients?
  23. Social Media, E-Health, and Medical Ethics
  24. Psychiatric Professionalism for the 21st Century
  25. Implications of Zero Suicide for Suicide Prevention Research
  26. Policing Compliance: Digital Medicine and Criminal Justice-Involved Persons
  27. Bedless Psychiatry—Rebuilding Behavioral Health Service Capacity
  28. County Jail or Psychiatric Hospital? Ethical Challenges in Correctional Mental Health Care
  29. Comparing Patient, Clinician, and Caregiver Perceptions of Care for Early Psychosis: A Free Listing Study
  30. Nonvoluntary Psychiatric Treatment Is Distinct From Involuntary Psychiatric Treatment
  31. Expanding Our Lens: Thinking Beyond Genomics
  32. Taking Issue With Crime, Vulnerability, and AOT
  33. “Restricted Community Members”: Research Protections and Opportunities for Individuals Committed to Assisted Outpatient Treatment
  34. Diagnosing, Disclosing, and Documenting Borderline Personality Disorder: A Survey of Psychiatrists' Practices
  35. Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence
  36. The Ethics of Behavioral Health Information Technology
  37. Psychosis Risk: What Is It and How Should We Talk About It?
  38. From Alienism to ACOs: Integrating Psychiatry, Again
  39. Research Moratoria and Off-Label Use of Ketamine
  40. Assent as an ethical imperative in the treatment of ADHD
  41. Expanding Long-term Care Options for Persons With Serious Mental Illness—Reply
  42. Improving Long-term Psychiatric Care
  43. Views about responsibility for alcohol addiction and negative evaluations of naltrexone
  44. Naturalism and the social model of disability: allied or antithetical?
  45. Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder
  46. Euthanasia for Minors in Belgium—Reply
  47. Pediatric Euthanasia in Belgium
  48. Assessing Decision-Making Capacity: A Primer for the Development of Hospital Practice Guidelines
  49. Defining mental illnesses: can values and objectivity get along?
  50. The Ethical Boundaries of Patient and Advocate Influence on DSM-5
  51. Deceiving Without Debriefing: A Pragmatic Overreach?
  52. Paradigms of Addiction and Evidence for Addiction Medication
  53. What We Owe the Psychopath: A Pragmatic Reply
  54. Immune to addiction: the ethical dimensions of vaccines against substance abuse
  55. A plea for virtue in ethics.
  56. There He Is … Master of Bioethics
  57. Help Wanted: Entrepreneurs Needed to Serve Bioethics' Outsiders